Race Oncology Ltd has released a press release.
September 2018 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Appendix 4E & Financial Statements
- June 2018 Quarterly Report
- FDA Grants Bisantrene Rare Paediatric Disease Designation
- Bisantrene poster presented at French Leukaemia Conference
- Bisantrene approval in UK for supply as unlicensed medicine
Later from Racura Oncology
- Race appoints Biosynergy to pursue Bisantrene licensing
- Race signs agreement for Bisantrene NPP in Israel
- Race appoints leading haematologist to support Bisantrene
- Race Receives $228k R&D Tax Incentive Refund
- Principal Investigator appointed for Bisantrene
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology